News Briefs: CMS Unveils Three Models Aimed at Lowering Drug Costs
CMS on Feb. 14 said the HHS Secretary has chosen three new models for testing by the CMS Innovation Center to help lower prescription drug costs, promote accessibility to life-changing drug therapies, and improve quality of care. The three models address the themes outlined in President Joe Biden’s executive order on lowering drug costs and meet the selection criteria thresholds of affordability, accessibility and feasibility of implementation, according to a Feb. 14 press release. First, the Medicare High-Value Drug List Model will encourage Part D plans to offer a low, fixed copayment across all cost-sharing phases of the Part D benefit for a standardized Medicare list of generic drugs that treat chronic conditions. Patients’ out-of-pocket costs for these generic drugs will be capped at a maximum of $2 per month per drug. Under the second model, the Cell and Gene Therapy Access Model, state Medicaid agencies will assign CMS to coordinate and administer multi-state, outcomes-based agreements with manufacturers for certain cell and gene therapies. Finally, under the Accelerating Clinical Evidence Model, CMS will develop payment methods for drugs approved under accelerated approval, in consultation with the Food and Drug Administration, to encourage timely confirmatory trial completion and improve access to post-market safety and efficacy data. This would reduce Medicare spending on drugs that have no confirmed clinical benefit, CMS stated.
Related Posts

News Briefs: Suit Accuses UnitedHealth of Using AI to Wrongfully Deny MA Care
READ MORE
Operationalizing MA Supplemental Benefits, Network Adequacy Proposals Could Impact Stars
READ MORE